Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
The molecular analysis performed in an HIV-hepatitis B virus (HBV) coinfected patient revealed selection of an unusual HBV polymerase mutation (rtV191I) during tenofovir-containing therapy, conferring simultaneously immune escape by HBsAg negativity and resistance to lamivudine but not tenofovir. Phenotypic analysis revealed impaired replicative capacity of mutants, which could be restored by concomitant precore or basal core promoter mutations (HBe-antigen-negativity). HBV mutants carrying drug and vaccine resistance may represent a considerable individual risk and public health concern.
Amini-Bavil-Olyaee
Samad
S
Department of Medicine III, University Hospital Aachen, Germany.
Sheldon
Julie
J
Lutz
Thomas
T
Trautwein
Christian
C
Tacke
Frank
F
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D015684:Gene Products, pol / Q000235:genetics; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics* / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D009154:Mutation; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir; D014779:Virus Replication / Q000235:genetics
D000998:Antiviral Agents; D015684:Gene Products, pol; D006514:Hepatitis B Surface Antigens; D063065:Organophosphonates; C066027:P protein, Hepatitis B virus; D019259:Lamivudine; D000068698:Tenofovir; D000225:Adenine